• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Phase Forward Revenues Up 27%, CFO to Retire

Phase Forward Revenues Up 27%, CFO to Retire

February 6, 2009
CenterWatch Staff

Waltham, Mass.-based eClinical technology company Phase Forward reported a strong fourth quarter and year end 2008, posting a 27% increase in revenues for the year and a 28% increase in revenues in Q4 compared with  the same period last year.

Revenues for the full year 2008 were $170.2 million, up from $134.3 million for 2007. Revenues for the fourth quarter were $48.3 million, up from $37.8 million in Q4 last year. According to a company release, this is Phase Forward’s 18th consecutive quarter of growth since its IPO in 2004.

Despite an increase in revenues, net income for the company fell year-over-year from $29.2 million, or $0.72 per diluted share, in the full year 2007 to $13.8 million, or $0.32 per diluted share, for the full year 2008. Net income for the fourth quarter was $5.8 million, or $0.13 per diluted share, which was at the high end of the company’s guidance of $0.12 to $0.13.

Phase Forward forecast strong revenue growth for 2009 but warned that current economic conditions could provide challenges. For the full year 2009, the company expects non-GAAP revenues to be between $200 and $205 million.

 “The fourth quarter was a strong finish to a highly successful year for Phase Forward, with both the traditional Phase Forward business as well as our recently acquired Clarix™ offering delivering better than expected revenues. We were particularly pleased to sign multi-million dollar, multi-year contract extensions and expansions with some of the largest companies in the pharmaceutical industry, said Phase Forward president and CEO Bob Weiler in a company release. “In addition, the continued traction of our CRO partnering strategy contributed to over 40% growth in our CRO-related revenues during the fourth quarter."

Phase Forward also announced that chief financial officer Rodger Weismann will retire June 1, 2009. Current vice president of finance Chris Menard will replace Weismann as CFO.

Upcoming Events

  • 15Apr

    Five Telltale Signs You’re Ready for an Electronic TMF System

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Clinical-Trial-Brainstorming

    FDA, Industry Tackle Problem of Including Older Adults in Trials

  • ClinicalTrialNetwork-360x240.png

    National Community-Based Research Network Would Improve Reach of Trials

  • Bottleneck-360x240.png

    Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Genetic Research and IBC Oversight Requirements

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing